Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Cell Block in Tumor Pathology, Molecular Diagnostics and Analysis
share announcement

Cell Block in Tumor Pathology, Molecular Diagnostics and Analysis

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 5564

Special Issue Editors

Prof. Dr. Akira Hara

E-Mail Website
Guest Editor
Department of Tumor Pathology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan
Interests: pathology; neuropathology; stem cell; immunohistochemistry; regenerative medicine; cancer; oncogene
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Hiroyuki Tomita

E-Mail Website
Guest Editor
Department of Tumor Pathology, Gifu University School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
Interests: pathology; tumor microenvironment; carcinogenesis; stem cell; mouse models
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The cell block (CB), a type of preparation by which cytological material is compacted into a pellet, fixed in formalin and embedded in paraffin, offers many advantages for molecular diagnostics over other cytological preparations. CB can also be archived for the future molecular analysis, unlike the cytological smear methods. In particular, CB preparation is extremely effective in the exfoliative cytology of body cavity fluids, including malignant pleural or abdominal effusion. CB can provide useful data in advanced technologies such as cancer genome or cancer stem cell analysis, even in patients with end-stage cancers where biopsy materials cannot be easily obtained by the usual methods. Furthermore, next-generation sequencing (NGS)-based companion diagnostics protocols that are already standardized for archival formalin-fixed paraffin-embedded specimens can be used in CB. Thus, the clinical usefulness of CB is increasing more and more in recent years. In this Special Issue, authors are invited to submit original articles that describe the advanced technologies such as NGS-based cancer genome or cancer stem cell analysis by means of the use of CB preparations. Review articles describing a broad range of advanced topics of CB preparations are also welcome.

This is the joint Special Issue both in IJMS and Diagnostics

Prof. Dr. Akira Hara
Prof. Dr. Hiroyuki Tomita
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cell block
  • Cytology
  • Effusion
  • Formalin
  • Paraffin block
  • Cancer genome
  • Cancer stem cell
  • Tumor pathology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2807 KiB  
Article
Diagnosis of Hodgkin Lymphoma from Cell Block: A Reliable and Helpful Tool in “Selected” Diagnostic Practice
by Paola Parente, Claudia Covelli, Magda Zanelli, Domenico Trombetta, Illuminato Carosi, Cristiano Carbonelli, Marco Sperandeo, Luca Mastracci, Giovanni Biancofiore, Maurizio Zizzo, Marco Taurchini, Stefano Ascani and Paolo Graziano
Diagnostics 2020, 10(10), 748; https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics10100748 - 25 Sep 2020
Cited by 3 | Viewed by 2200
Abstract
Background: The diagnosis of lymphoma requires surgical specimens to perform morphological evaluation, immunohistochemical and molecular analyses. Ultrasound-guided fine needle aspiration may represent an appropriate first approach to obtain cytological samples in impalpable lesions and/or in patients unsuitable for surgical procedures. Although cytology has [...] Read more.
Background: The diagnosis of lymphoma requires surgical specimens to perform morphological evaluation, immunohistochemical and molecular analyses. Ultrasound-guided fine needle aspiration may represent an appropriate first approach to obtain cytological samples in impalpable lesions and/or in patients unsuitable for surgical procedures. Although cytology has intrinsic limitations, the cell block method may increase the possibility of achieving an accurate diagnosis. Methods: We retrospectively selected a total of 47 ultrasound-guided fine needle aspiration and drainage samples taken from patients with effusion and deep-seated lesions which are clinically suspicious in terms of malignancy. Results: In 27 cases, both cell block and conventional cytology were performed: 21/27 cell blocks were adequate for the diagnosis of lymphoma and suitable for immunocytochemistry and molecular analyses vs. 12/20 samples to which only conventional cytology was applied. Moreover, in five patients we were able to make a diagnosis of Hodgkin lymphoma with the cell block (CB) technique. Conclusions: Contrary to conventional cytology, the cell block method may allow immunocytochemistry and molecular studies providing useful information for the diagnosis and subtypization of lymphoma in patients unsuitable for surgical procedure or with deep-seated lesions or extra-nodal diseases; additionally, it is a daily, simple and helpful approach. Moreover, we describe the usefulness of cell blocks in the diagnosis of Hodgkin lymphoma. Full article
(This article belongs to the Special Issue Cell Block in Tumor Pathology, Molecular Diagnostics and Analysis)
►▼ Show Figures

Figure 1

10 pages, 1386 KiB  
Article
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
by Michela Palleschi, Roberta Maltoni, Sara Ravaioli, Alessandro Vagheggini, Francesca Mannozzi, Francesca Fanini, Francesca Pirini, Maria Maddalena Tumedei, Eleonora Barzotti, Lorenzo Cecconetto, Samanta Sarti, Silvia Manunta, Paola Possanzini, Anna Fedeli, Annalisa Curcio, Mattia Altini, Ugo De Giorgi, Andrea Rocca and Sara Bravaccini
Diagnostics 2020, 10(8), 573; https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics10080573 - 08 Aug 2020
Cited by 15 | Viewed by 2801
Abstract
CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expression of progesterone receptor (PR) and Ki67, assessed by immunohistochemistry, in [...] Read more.
CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expression of progesterone receptor (PR) and Ki67, assessed by immunohistochemistry, in 71 ABC patients treated with CDK4/6i and analyzed the impact of these markers on progression-free survival (PFS). The majority of patients 63/71 (88.7%) received palbociclib, 4 (5.6%) received ribociclib, and 4 (5.6%) received abemaciclib. A higher median value of Ki67 was observed in cases undergoing second-line treatment (p = 0.047), whereas the luminal B subtype was more prevalent (p = 0.005). In the univariate analysis of the first-line setting, luminal A subtype showed a trend towards a correlation with a longer PFS (p = 0.053). A higher continuous Ki67 value led to a significantly shorter PFS. When the interaction between pathological characteristics and line of treatment was considered, luminal B subtype showed a significantly (p = 0.043) worse outcome (Hazard Ratio (HR) 2.84; 1.03–7.82 95% Confidence Interval (CI)). PFS in patients undergoing endocrine therapy plus CDK4/6i was inversely correlated with Ki67 expression but not with PR, suggesting that tumor proliferation has a greater impact on cell cycle inhibitors combined with endocrine therapy than PR expression. Full article
(This article belongs to the Special Issue Cell Block in Tumor Pathology, Molecular Diagnostics and Analysis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop